Back Login for AI Analysis

    ARTV (STOCKS)

    Artiva Biotherapeutics, Inc. Common Stock

    $11.200000
    -0.330000 (-2.86%)
    Prev close: $11.530000
    Company Information
    Exchange
    XNAS
    Sector
    Health Technology
    Industry
    Pharmaceuticals: Other
    CEO
    Fred Aslan
    Asset Type
    stocks
    Website
    Visit
    Fundamentals
    Market Cap
    $590.42M
    Employees
    105
    P/E (TTM)
    -3.48
    P/B (TTM)
    1.62
    Dividend Yield
    Technical Indicators
    SMA 10
    SMA 20
    SMA 50
    EMA 9
    EMA 21
    RSI
    MACD State
    Recent News

    No recent news found for this ticker.

    Financial Statements
    TTM (Jun 2026)
    Revenues $0.00
    Nonoperating Income/Loss $5.33M
    Operating Expenses $96.15M
    Research and Development $75.86M
    Other Operating Expenses $20.29M
    Operating Income/Loss -$96.15M
    Income/Loss From Continuing Operations After Tax -$90.82M
    Income/Loss From Continuing Operations Before Tax -$90.82M
    Net Income/Loss -$90.82M
    Net Income/Loss Attributable To Noncontrolling Interest $0.00
    Net Income/Loss Attributable To Parent -$90.82M
    Net Income/Loss Available To Common Stockholders, Basic -$90.82M
    Participating Securities, Distributed And Undistributed Earnings/Loss, Basic $0.00
    Preferred Stock Dividends And Other Adjustments $0.00
    Basic Earnings Per Share -$3.23
    Diluted Earnings Per Share -$3.23
    Basic Average Shares 56,610,958
    Diluted Average Shares 56,610,958
    Assets $368.63M
    Current Assets $352.28M
    Cash $349.40M
    Other Current Assets $2.88M
    Noncurrent Assets $16.36M
    Fixed Assets $5.67M
    Other Non-current Assets $10.69M
    Liabilities $21.13M
    Current Liabilities $14.58M
    Accounts Payable $1.39M
    Wages $4.64M
    Other Current Liabilities $8.55M
    Noncurrent Liabilities $6.55M
    Equity $347.50M
    Equity Attributable To Noncontrolling Interest $0.00
    Equity Attributable To Parent $347.50M
    Liabilities And Equity $368.63M
    Net Cash Flow From Operating Activities -$75.23M
    Net Cash Flow From Operating Activities, Continuing -$75.23M
    Net Cash Flow From Investing Activities $65.22M
    Net Cash Flow From Investing Activities, Continuing $65.22M
    Net Cash Flow From Financing Activities $283.00M
    Net Cash Flow From Financing Activities, Continuing $283.00M
    Net Cash Flow $272.99M
    Net Cash Flow, Continuing $272.99M
    Comprehensive Income/Loss -$90.72M
    Comprehensive Income/Loss Attributable To Noncontrolling Interest $0.00
    Comprehensive Income/Loss Attributable To Parent -$90.84M
    Other Comprehensive Income/Loss -$67.21M